Literature DB >> 8352218

Hyperinsulinism as a marker in obese children.

R Zannolli1, A Rebeggiani, F Chiarelli, G Morgese.   

Abstract

OBJECTIVE: To determine the relationship between insulin and the metabolic profile and eventual weight loss in obese children.
DESIGN: We first attempted to define the metabolic profile for 18 obese children; we then studied weight loss in this group longitudinally.
SETTING: Department of Pediatrics in a university hospital. PARTICIPANTS: Eighteen randomly selected, young, obese male subjects from 5 to 16 years of age.
INTERVENTIONS: (1) Metabolic screening at the outset, including insulinemia and glycemia after the oral glucose tolerance test and plasma levels of total cholesterol, high-density lipoprotein cholesterol, and triglycerides, and (2) weight loss treatment.
RESULTS: We divided the sample into "normoinsulinemic" and "hyperinsulinemic" groups, similar for all the variables tested except for weight loss and plasma triglyceride levels. A direct relationship between weight loss results and duration of treatment was found for the entire group. The "hyperinsulinemic" group had a lower percentage reduction in excess weight, and the results in this group were not dependent on the duration of treatment.
CONCLUSIONS: The effort to keep "normoinsulinemic" obese children in treatment may be useful; it is advisable to study "hyperinsulinemic" children more in depth.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8352218     DOI: 10.1001/archpedi.1993.02160320039016

Source DB:  PubMed          Journal:  Am J Dis Child        ISSN: 0002-922X


  9 in total

1.  The absence of insulin resistance in metabolic syndrome definition leads to underdiagnosing of metabolic risk in obese patients.

Authors:  Selim Kurtoglu; Leyla Akin; Mustafa Kendirci; Nihal Hatipoglu; Ferhan Elmali; Mümtaz Mazicioglu
Journal:  Eur J Pediatr       Date:  2012-03-28       Impact factor: 3.183

2.  Suppression of insulin secretion is associated with weight loss and altered macronutrient intake and preference in a subset of obese adults.

Authors:  P A Velasquez-Mieyer; P A Cowan; K L Arheart; C K Buffington; K A Spencer; B E Connelly; G W Cowan; R H Lustig
Journal:  Int J Obes Relat Metab Disord       Date:  2003-02

3.  Protein oxidation in obesity and insulin resistance.

Authors:  M Emre Atabek; Mehmet Keskin; Cevat Yazici; Mustafa Kendirci; Nihal Hatipoglu; Esat Koklu; Selim Kurtoglu
Journal:  Eur J Pediatr       Date:  2006-05-19       Impact factor: 3.183

4.  Prevalence and risk factors of metabolic syndrome in obese children and adolescents: the role of the severity of obesity.

Authors:  Yasar Sen; Nurgun Kandemir; Ayfer Alikasifoglu; Nazli Gonc; Alev Ozon
Journal:  Eur J Pediatr       Date:  2008-01-17       Impact factor: 3.183

5.  Racial differences in glucagon-like peptide-1 (GLP-1) concentrations and insulin dynamics during oral glucose tolerance test in obese subjects.

Authors:  P A Velasquez-Mieyer; P A Cowan; G E Umpierrez; R H Lustig; A K Cashion; G A Burghen
Journal:  Int J Obes Relat Metab Disord       Date:  2003-11

6.  Insulin resistance in obese children and adolescents: HOMA-IR cut-off levels in the prepubertal and pubertal periods.

Authors:  Selim Kurtoğlu; Nihal Hatipoğlu; Mümtaz Mazıcıoğlu; Mustafa Kendirici; Mehmet Keskin; Meda Kondolot
Journal:  J Clin Res Pediatr Endocrinol       Date:  2010-08-02

7.  β-3AR W64R Polymorphism and 30-Minute Post-Challenge Plasma Glucose Levels in Obese Children.

Authors:  Hasibe Verdi; Sibel Tulgar Kınık; Yaprak Yılmaz Yalçın; Nursel Muratoğlu Şahin; Ayşe Canan Yazıcı; F Belgin Ataç
Journal:  J Clin Res Pediatr Endocrinol       Date:  2015-03

8.  The Diagnosis of Prediabetes in Adolescents.

Authors:  Vera Zdravković; Silvija Sajić; Jadranka Mitrović; Igor Stefanović; Polina Pavićević; Dimitrije Nikolić; Jovana Dimić; Nebojša M Lalić
Journal:  J Med Biochem       Date:  2014-10-08       Impact factor: 3.402

9.  Antidiabetic efficacy of lactoferrin in type 2 diabetic pediatrics; controlling impact on PPAR-γ, SIRT-1, and TLR4 downstream signaling pathway.

Authors:  Waleed A Mohamed; Mona F Schaalan
Journal:  Diabetol Metab Syndr       Date:  2018-12-04       Impact factor: 3.320

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.